Field-Based Psychopharmacology: Mapping Medications onto Consciousness Dynamics
A reconceptualisation of psychiatric prescribing through the lens of a field theory which moves beyond disease-centred models towards understanding medications as modulators of consciousness parameters.
Navigating This Deck
This card provides an overview of the structure and invites readers to explore at their own pace.
This deck is organized as a journey from epistemological foundation through theoretical framework to clinical application. You're invited to traverse it in whatever way serves your learning—linearly, by jumping to sections of interest, or by following the labyrinth of interconnected resources.
The Structure:
Foundation
Why conventional frameworks fall short, and what field-based thinking offers
Theoretical Architecture
The biological substrate (neuroinflammation), cognitive architecture (wild-type cognition), and developmental context (transformation programme)
Field Parameters
G (Ground/Containment), Γ (Reflection), Δ² (Difference), H (Harmonic Coefficient)
Medication Mapping
Understanding what medications actually do to consciousness dynamics, organized by class
Clinical Application
Questions before prescribing, case vignettes, and field-based reasoning in practice
Deprescribing
The art of supporting people to reduce or discontinue medications safely
Integration
Connecting to the broader labyrinth of resources
A Note on Approach:
This framework is offered as invitation, not prescription. The medication mappings represent one lens for understanding psychopharmacology—a way of thinking rather than a validated protocol. Your clinical wisdom and the lived experience of those you work with remain the most important guides.
We're sun, not north wind. Gentle inquiry rather than forceful certainty.
Field Theory within Spiral State Psychiatry:
This deck applies field theory - a specific framework within Spiral State Psychiatry - to understand medication effects on consciousness dynamics. Field theory uses mathematical metaphors (G, Γ, Δ², H) to model consciousness as a dynamic system, providing precise language for what medications actually do to field parameters. This analytical lens complements other Spiral State approaches:
- K (the relational field) - the therapeutic presence that precedes intervention
- Embodiment practices - breathwork, movement, somatic awareness
- Rhythm and regulation - working with natural cycles of activation and rest
- Ecological awareness - understanding nested systems from individual to environment
- Cultural humility - honoring diverse healing traditions
Field theory offers clinicians a rigorous framework for psychopharmacological reasoning while remaining grounded in the broader Spiral State commitment to presence-centered, relationship-based care. The parameters help us think clearly about medication mechanisms without reducing healing to purely pharmaceutical intervention.
Conceptual Foundation
From Disease-Centred to Field-Centred Prescribing
Contemporary psychopharmacology operates within a fundamentally flawed paradigm. The disease-centred model positions medications as correctives for putative chemical imbalances or treatments for discrete disorders. This framework, whilst superficially coherent, obscures the actual dynamics of what occurs when we introduce psychotropic substances into human consciousness.
The field-centred approach offers a more epistemologically honest alternative. Rather than claiming to "correct" or "treat", we acknowledge that medications temporarily modulate parameters of conscious experience. They create conditions—sometimes helpful, sometimes iatrogenic—that either support or impede a person's capacity to navigate their own psychological landscape.
This shift demands uncomfortable honesty about what we're actually doing when we prescribe. We're not fixing broken brains. We're altering field dynamics in ways that may facilitate growth or may substitute chemical intervention for the difficult work of developing genuine psychological capacity. The distinction matters profoundly for both ethics and outcomes.
New to Field Theory?
If these concepts intrigue you, Spiral State Psychiatry is the foundational framework that reframes mental distress as consciousness field disruption rather than disease. Here, you'll uncover the "why" behind the field-based approach, exploring E=GΓΔ², the Harmonic Coefficient, and how depression, anxiety, trauma, and psychosis can be understood through field dynamics rather than rigid diagnostic categories. It offers hope and a profound paradigm shift, making sense of what medications actually do.
Disease-Centred Claim
"Corrects chemical imbalance"
Field-Centred Reality
Temporarily modulates field parameters
Disease-Centred Claim
"Treats the disorder"
Field-Centred Reality
Creates conditions for process completion or consciousness literacy development
Disease-Centred Claim
"Maintenance therapy"
Field-Centred Reality
Bridge whilst building capacity
Evidence Base: The chemical imbalance theory lacks empirical support (Moncrieff 2022 umbrella review). For comprehensive analysis: Critical Insights into Contemporary Psychiatric Practice
Conventional Framing
- "Relapse prevention"
- "Side effects"
- "Therapeutic dose"
- "It works"
- "Evidence-based treatment"
Field-Based Translation
- Dependency creation if Cl not developed
- Integral effects we've decided to ignore
- Minimum effective field modulation
- Compared to what outcome? At what cost to Cl?
- Evidence within a contaminated paradigm
The language we use shapes clinical reality. Disease-centred terminology conceals power dynamics, obscures uncertainty, and pathologises normal responses to abnormal circumstances. Field-centred language demands precision about what we know, what we're doing, and what remains unknown.
The Central Question
Before any prescription, the field-based clinician must pause and genuinely ask: What field parameter is destabilised, and will chemical modulation support or impede this person's capacity to navigate their own consciousness?
This is not rhetorical flourish. It's a fundamental shift in clinical stance. The question refuses the automatic leap from symptom to prescription, demanding instead careful phenomenological mapping of what's actually occurring in this particular consciousness at this particular moment.
Most critically, the question includes its shadow: "Will this intervention impede capacity development?" We must hold the uncomfortable possibility that our prescription, however well-intentioned, may substitute chemical suppression for the difficult, necessary work of building psychological capability. Sometimes the most therapeutic choice is pharmaceutical restraint.
Critical Epistemology
The Contaminated Evidence Base
Here we must confront an uncomfortable truth that pervades all of psychiatry: the entire evidence base for psychiatric medications is structurally contaminated by the invalid categorical frameworks within which it was generated. This is not mere academic pedantry—it undermines every efficacy claim, every treatment guideline, every "evidence-based" recommendation.
The fundamental problem is this: all psychiatric medication research is conducted using DSM/ICD categories as if they represented valid disease entities. They do not. These are administrative conveniences, reified into pseudo-diseases through repetition and institutional momentum. When we claim a medication is "effective for major depression" or "treats schizophrenia", we're making category errors from the ground up.
Research populations defined by invalid categories are necessarily heterogeneous groups incorrectly assumed to be homogeneous. "Major depression" encompasses wildly different phenomenological experiences, aetiologies, and consciousness dynamics, yet we treat it as a unitary entity for research purposes. This creates statistical noise masquerading as signal, effect sizes that obscure more than they reveal.
For Deeper Exploration
This epistemological critique draws from a comprehensive analysis of contemporary psychiatric evidence: Critical Insights into Contemporary Psychiatric Practice
The site examines the chemical imbalance myth, modest antidepressant efficacy (NNT often >16), withdrawal realities, and Moncrieff's drug-centred model—providing the empirical foundation for field-based reconceptualization.
Key Theoretical Foundation
For Comprehensive Theoretical Foundation
The convergent evidence from topological neuroscience, critical psychiatry, psychedelic science, and systems biology is synthesized in The Dimensional Poverty of Psychiatric Epistemology—a rigorous academic paper demonstrating why psychiatric diagnosis operates in radically impoverished dimensional space compared to actual consciousness dynamics.
This paper provides the complete theoretical architecture showing how independent research programs across multiple disciplines have arrived at complementary insights that support field-based frameworks.
What This Means for Field-Based Practice
1
Translation, Not Validation
The medication mappings in this document represent clinical observation and mechanistic reasoning, not validated field-based research (which doesn't yet exist). We're translating drug-centred knowledge into field-centred understanding, using receptor binding profiles as proxies for field parameter effects.
2
Inherited Problems
The field framework may offer superior explanatory power to disease-centred models, but it inherits the epistemological problems of a pharmacopoeia developed entirely within a paradigm it critiques. We cannot simply port findings across paradigms and assume validity transfers.
3
Provisional Knowledge
Everything here must be held provisionally. These are hypotheses for clinical reasoning, not validated treatment protocols. The framework offers tools for thinking more clearly about consciousness dynamics, whilst acknowledging our knowledge base is fundamentally compromised.
Hard Outcomes Versus Category-Dependent Outcomes
Hard Outcomes
Some outcomes are less category-dependent and therefore more trustworthy:
- Death (particularly suicide)
- Hospitalisation rates
- Employment stability
- Relationship continuity
- Housing security
These remain meaningful regardless of diagnostic framework validity.
Soft Outcomes
These inherit all validity problems of the diagnostic categories:
- Symptom rating scales
- "Remission" rates
- Clinical Global Impression scores
- Diagnosis-specific "response"
These are measuring arbitrary thresholds within invalid categories.
This distinction explains why lithium's anti-suicide evidence may be more meaningful than its "efficacy for bipolar disorder". Suicide is a hard outcome not dependent on categorical validity. "Mood stabilisation" in a dimensionally impoverished construct is epistemologically suspect.
Clinical Implication
Use this framework as a lens for clinical reasoning, not as validated treatment protocol. The goal is to think more clearly about what medications do to consciousness dynamics, whilst acknowledging that our knowledge base is structurally compromised by the paradigms within which it was generated.
Field Mechanics
Field Parameter Definitions: Pharmacological Context
To map medications onto consciousness dynamics, we must first establish precise definitions of the field parameters we're modulating. These are not metaphors—they represent actual dimensions of conscious experience that psychiatric medications alter, sometimes helpfully, sometimes iatrogenically.
Understanding these parameters allows us to move beyond crude symptom-suppression models towards nuanced appreciation of how chemical interventions ripple through the complex system of human consciousness. Each parameter interacts with others; interventions that stabilise one may destabilise another.
The Neuroinflammatory Substrate
The field parameters (G, Γ, Δ², H) don't operate in a vacuum—they emerge from biological processes. Neuroinflammation provides the mechanistic link between medication effects and consciousness dynamics.
The Unified Mechanism
Chronic neuroinflammation → microglial activation → cytokine cascade (IL-1β, IL-6, TNF-α) → NMDA receptor dysfunction → consciousness field disruption
This pathway explains why seemingly distinct conditions (ADHD, OCD, ASD, PTSD, burnout) respond to similar field-based interventions: they share a common neuroinflammatory substrate.
Implications for Medication Mapping
Antipsychotics suppress Δ² partly by dampening inflammatory signaling
SSRIs may work (when they do) through anti-inflammatory effects, not serotonin per se
Stimulants in ADHD enhance signal-to-noise by modulating inflammatory noise
Lithium's neuroprotective effects include anti-inflammatory mechanisms
The Missing Link
Conventional psychopharmacology lacks a biological substrate for its claims. The neuroinflammatory framework provides one—connecting molecular mechanisms to subjective experience through consciousness field dynamics.
For Deeper Exploration:
Spiral Neuropsychiatry - Hemispheric integration, mirror neurons, psycho-immunology
Neuroinflammatory Consciousness Field Theory - Unified cross-diagnostic framework
Neuroinflammatory Consciousness Field Theory - Unified cross-diagnostic framework
Wild-Type Cognition: The Missing Variable
What psychiatry diagnoses as "severe mental illness" often represents wild-type cognitive architecture encountering domesticated systems under neuroinflammatory stress.
Wild-type minds have: high Δ² sensitivity (pattern recognition), high Γ capacity (meta-cognitive depth), high G dependence (need for coherent container).
This creates dual vulnerability: environmental incoherence (systemic Δ) + biological inflammation (disrupting field coherence).
The neuroinflammatory-wild-type interaction explains why certain nervous systems are particularly vulnerable to field disruption.
For a deeper dive into this concept, visit: Wild-Type Cognition: The Missing Variable
The Transformation Programme: What Psychiatry Doesn't Recognize
Human neurology includes an endogenous transformation programme—a structured sequence of psychological dissolution and reconstitution that activates when existing self-structure becomes inadequate to meet reality. This is not pathology—it's what healthy adaptive systems do when current organization cannot handle environmental demands.
The programme follows consistent phenomenological patterns across cultures: separation → ego dissolution → symbolic death → encounter → reconstitution → return. Foraging societies developed transformation technologies (initiation rites, shamanic practices, vision quests) that engaged this programme deliberately, providing containment, meaning, and integration.
When transformation technology is destroyed (colonization, industrialization), the programme still triggers but cannot complete → arrested transformation presenting as chronic mental illness.
The distinguishing feature between 'successful transformation' and 'chronic mental illness' is not neural signature but whether meaning and purpose can be found—whether adequate container, recognition, and integration support exists.
For a deeper dive into this concept, visit: The Transformation Programme: What Psychiatry Doesn't Recognize
G: Ground/Containment
The stability of the field container—the holding environment within which conscious experience occurs.
Physiological Layer
- Autonomic nervous system regulation
- Sleep architecture integrity
- Arousal modulation capacity
- Baseline physiological coherence
Relational Layer
- Felt sense of safety in interpersonal space
- Attachment security
- Environmental stability
Cognitive Layer
- Capacity to hold experience without fragmentation
- Tolerance for emotional intensity
- Structural integrity of self-concept
Γ (Gamma): Reflection
Meta-cognitive and self-modelling capacity—the system's ability to observe and comprehend its own states.
Salience Systems
- Appropriate attribution of significance
- Attention regulation and direction
- Signal-to-noise discrimination
Self-Recognition
- Narrative coherence across time
- Capacity to recognise one's patterns
- Integration of experience into self-model
Meta-Awareness
- Capacity to observe one's own cognitive processes
- Perspective-taking on one's emotional states
- Reflective rather than purely reactive processing
Δ² (Delta-Squared): Difference
Novelty, disruption, and creative-chaotic input—the signal that demands integration or response.
Trauma Activation
- Historical material resurfacing
- Trigger-response patterns
- Unprocessed experience demanding attention
Neurodivergent Signal
- Cognitive architecture mismatch with environment
- Sensory processing intensity
- Executive function demands exceeding capacity
Novel Information
- Unexpected events requiring integration
- Threatening information
- Creative insights disrupting current models
H: Harmonic Coefficient (Overall Field Coherence)
The Harmonic Coefficient represents the overall coherence of consciousness dynamics—how the field parameters interact to produce integrated experience versus fragmentation. This is not a static measure but a dynamic indicator of system-level functioning.
1
H > 1: Runaway Amplification
Mania, agitation, psychotic elaboration. The system amplifies signal beyond integration capacity, creating increasingly unstable feedback loops. Thoughts race faster than reflection can process; affect intensifies beyond containment.
2
H ≈ 1: Optimal Coherence
Flow states, integrated functioning, adaptive responsiveness. Signal is neither suppressed nor overwhelming. G provides adequate containment, Γ remains functional, Δ² is processed rather than avoided or amplified.
3
H → 0: Collapsed Dynamics
Depression, anhedonia, frozen states. The system loses responsiveness; nothing feels significant; motivation collapses. Δ² may still arrive but generates no response. The field approaches quiescence.
4
H < 0: Dissolution States
Psychosis, dissociation, derealisation. Coherence breaks down entirely. Self-world boundaries become permeable; narrative continuity fragments; field integrity dissolves. This is not merely low functioning—it's structural disintegration.
Approaching the Medication Mappings
The following section maps psychiatric medications onto field parameters—exploring what these substances appear to do to consciousness dynamics rather than which 'disorders' they 'treat.'
What These Mappings Offer:
- A lens for understanding medication effects through field dynamics (G, Γ, Δ², H)
- Clinical observations translated into field-based language
- Questions to consider rather than answers to accept
- A framework for thinking about suppression versus capacity-building
What These Mappings Are Not:
- Validated treatment protocols requiring adherence
- Definitive truths about how medications work
- Recommendations for or against specific medications
- Substitutes for clinical judgment and lived experience
The Approach:
These mappings represent clinical observations and theoretical translations. They're offered with intellectual honesty about the limitations of psychiatric evidence, the epistemological contamination of research, and the complexity of individual responses.
Some language may feel critical of current prescribing patterns. This critique comes from a place of wanting better for those we serve, not from dismissing the genuine relief some people find with medications.
The Invitation:
As you read, notice what resonates and what doesn't. Question the framework as rigorously as it questions conventional approaches. Your clinical experience—and the lived experience of those you work with—remains the ultimate arbiter of what's useful.
We're exploring together, not prescribing certainty.
Medication Mapping
Antipsychotics: The Δ² Suppressors
Antipsychotics represent psychiatry's bluntest instruments—medications designed primarily to suppress Δ² through dopaminergic blockade. The class name itself reveals the paradigm: "anti-psychotic" suggests correcting aberrant mental states, when the mechanism is actually broad suppression of novelty processing, salience attribution, and creative-chaotic signal.
Understanding antipsychotics through field theory reveals why they produce such variable outcomes. At low doses, they primarily force G through sedation (especially quetiapine). At moderate doses, they begin modulating Γ (salience processing). At high doses, they achieve profound Δ² suppression—but at tremendous cost to cognitive vitality, metabolic health, and subjective experience of being alive.
The field framework also illuminates why "atypicals" aren't genuinely different in kind from "typicals"—they're variations on the same theme of Δ² suppression through receptor blockade, with different side-effect profiles reflecting different receptor affinities rather than fundamentally distinct mechanisms.
Quetiapine (Seroquel): The Dose-Dependent Chameleon
The Quetiapine Prescription Pattern: A Field Critique
Common Clinical Pattern
- Initiated at 25mg for "emotional dysregulation"
- Patient reports some benefit (sleeps better)
- "It doesn't work" leads to dose escalation
- 50mg, 100mg, 200mg, 400mg progression
- Eventually at antipsychotic doses for what began as insomnia
Field Translation
- Using sedation as pseudo-containment
- Sedation achieved but underlying G instability unchanged
- Chasing symptom suppression without addressing Ce = Cn - Cl dynamics
- Dose creep reflects failure to build genuine capacity
- Metabolic burden, cognitive blunting, withdrawal phenomena accumulate
Field-Aligned Alternative: If low-dose quetiapine provides temporary G support, this must be explicitly framed as chemical containment whilst relational, somatic, and environmental G are established. Taper planning should begin at initiation, not years later when dependence is entrenched.
Olanzapine (Zyprexa): The Sledgehammer
G: Ground/Containment
↑↑↑ Profound sedation via H1/muscarinic blockade. Maximum G-forcing available in oral antipsychotic form.
Γ: Reflection
↓↓ Significant cognitive blunting commonly reported. Meta-cognitive capacity impaired by sedation and anticholinergic effects.
Δ²: Difference
↓↓↓ Potent D2 and 5-HT2A blockade. Maximum suppression of novelty processing and salience attribution.
Metabolic Impact
Severe weight gain, insulin resistance, lipid dysregulation. The "treatment" creates new disease burden requiring additional medication.
Olanzapine represents maximum pharmacological suppression: profound Δ² dampening, forced G through sedation, and significant Γ impairment. Useful in acute overwhelming crises (H < 0 dissolution states) but extraordinarily high cost to long-term Cl development. The medication substitutes for capacity rather than supporting its development.
Risperidone (Risperdal): Tight D2 Binding
G: Containment
↑ Less sedating than quetiapine or olanzapine, providing G enhancement primarily through Δ² suppression rather than sedation.
Γ: Reflection
→ to ↓ Dose-dependent cognitive effects. At lower doses may preserve some function; higher doses impair.
Δ²: Novelty
↓↓↓ Very tight D2 binding creates robust suppression of dopaminergic signal. High extrapyramidal symptom risk.
The tight D2 binding that creates Δ² suppression also generates akathisia—a profoundly distressing inner restlessness that is itself G-destabilising. This creates an iatrogenic field disruption: the medication meant to stabilise instead introduces a new source of dysregulation. Additionally, prolactin elevation represents endocrine field disruption with downstream effects on sexual function, bone density, and overall physiology.
Aripiprazole (Abilify): The Partial Agonist
Field Parameters
- G: → Minimal sedation, can be activating (destabilises in already unstable systems)
- Γ: → to ↑ Partial D2 agonism may preserve cognitive function better than full antagonists
- Δ²: ↓ to ↓↓ Partial agonist mechanism creates ceiling effect—dampens excess without complete blockade
Aripiprazole's partial D2 agonism represents a different pharmacological strategy: modulation rather than suppression. In systems with excessive dopaminergic signalling, it acts as antagonist; in systems with low signalling, it provides partial agonism. This creates a theoretical ceiling—it shouldn't over-suppress.
However, the clinical puzzle: why does aripiprazole sometimes worsen agitation? Field answer: in a consciousness already G-destabilised, the activating properties further disrupt containment even whilst modulating Δ². The medication's pharmacological elegance doesn't guarantee field-level stabilisation. This reveals why receptor profiles don't determine outcomes—field context does.
Critical Analysis
Clozapine (Clozaril): The Supposed Anomaly
G: Containment
↑↑ Sedation present but complex; less crude than olanzapine. Some report improved overall stability not available with other antipsychotics.
Γ: Reflection
Variable. Intriguingly, some report cognitive clarity unavailable on other antipsychotics—improved capacity for reflection rather than blunting.
Δ²: Novelty
↓↓ Loose D2 binding with fast dissociation. Suppresses excess signal without the complete blockade of tight-binding antagonists.
The Clozapine Paradox: Epistemological Contamination
Clozapine is positioned as uniquely "effective for treatment-resistant schizophrenia"—gold standard evidence, multiple meta-analyses, apparent clinical confirmation. However, this narrative conceals profound category errors that make the efficacy claims fundamentally unverifiable.
The pathway to clozapine is so contaminated by system failures that we cannot know whether the apparent superior efficacy is genuine or artefactual. Consider: "treatment-resistant schizophrenia" requires prior failure of multiple antipsychotics, but those trials are often inadequate (wrong dose, insufficient duration, poor adherence). The diagnostic process leading to "schizophrenia" itself is frequently inadequate—trauma histories unexplored, neurodevelopmental conditions unrecognised, substance use confounding presentation.
By the time someone reaches clozapine, they've survived years of system failure: diagnostic error, inappropriate medication trials, accumulated iatrogenic harm, and progressive demoralisation. If clozapine "works" for this population, is it because of superior pharmacology or because it's finally prescribed with adequate care, monitoring, and therapeutic optimism?
The category "treatment-resistant schizophrenia" pathologises the person for system failures. It attributes non-response to individual biology rather than inadequate intervention. This makes comparative efficacy claims epistemologically suspect—we're comparing clozapine (prescribed carefully, with hope) to prior medications (often prescribed poorly, without adequate support).
Provisional Hypothesis
Clozapine's loose D2 binding with fast dissociation may allow more nuanced Δ² modulation—dampening excess signal without the complete blockade that impairs Γ. The multi-receptor effects (5-HT2A, muscarinic, adrenergic) create complex field modulation that may be better tolerated at the subjective level.
However, this remains speculative. We cannot confidently assert clozapine superiority given the contaminated pathway through which people arrive at it. The "clozapine anomaly" may be partly or wholly artefactual—a product of system failures misattributed as individual pharmacological response.
Clinical implication: If considering clozapine, ensure the person has actually had adequate prior trials (proper dosing, sufficient duration, with psychosocial support) and that "schizophrenia" represents a genuine phenomenological description rather than a reified administrative category.
Mood Stabilisers
Lithium: The Field Stabiliser
Lithium occupies unique space in the psychiatric pharmacopoeia. Unlike medications that suppress parameters, lithium appears to stabilise the field container itself—enhancing G without crushing Δ², supporting rather than impairing Γ. Its mechanisms involve circadian regulation, neuroprotection, and modulation of cellular signalling cascades that undergird consciousness dynamics.
The anti-suicide evidence for lithium is among the most robust in psychiatry—critically, this involves a hard outcome (death) rather than category-dependent measures like "mood episode prevention". People on lithium die less frequently by suicide. This finding transcends the validity problems of "bipolar disorder" as a category.
Lithium Field Parameters
G: Ground
↑ Circadian stabilisation creates more reliable physiological ground. Reduced reactivity to stressors. The system becomes less vulnerable to destabilisation from perturbation.
Γ: Reflection
→ to ↑ Neuroprotective effects (increased grey matter volume, BDNF modulation) may support reflective capacity. Some report improved capacity for self-observation rather than blunting.
Δ²: Novelty
Modulated rather than suppressed. GSK-3β inhibition may allow signal processing without overwhelming the system. The medication doesn't eliminate responsiveness—it contains it within manageable bounds.
The Lithium Complication: Monitoring and Toxicity
Clinical Benefits
- Anti-suicide evidence (hard outcome)
- May stabilise without suppressing
- Potentially supports Γ through neuroprotection
- Long track record, well-understood pharmacology
- Some report subjective improvement in capacity
Clinical Burdens
- Regular blood monitoring required (renal, thyroid, lithium level)
- Narrow therapeutic window (toxicity risk)
- Long-term nephrotoxicity—treatment damages kidneys
- Creates ongoing medical surveillance relationship
- Withdrawal can be destabilising
The monitoring requirements create ongoing medicalisation: regular blood tests, endocrinology referrals, renal function surveillance. This embeds the person in a system of medical oversight that may undermine autonomy and self-efficacy—the opposite of Cl development. Additionally, the very real risk of long-term nephrotoxicity means the "treatment" causes organ damage over time.
Epistemological Caution on Lithium
The evidence base showing lithium efficacy for "bipolar disorder" inherits all the validity problems of that diagnostic category. "Bipolar disorder" is a dimensionally impoverished construct that collapses heterogeneous presentations into a reified entity. If the category is invalid, what does "effective for bipolar disorder" actually measure?
The anti-suicide evidence may be more robust because suicide is a hard outcome not dependent on diagnostic frameworks. But efficacy claims for "mood stabilisation" or "episode prevention" are category-dependent measures built on invalid foundations.
Clinical implication: Lithium may be more field-aligned than other mood stabilisers—it stabilises without suppressing. However, this cannot be confidently asserted given the contaminated evidence base. The requirement for ongoing monitoring and long-term toxicity risk create dependencies that may undermine Cl development regardless of pharmacological mechanism. Each case demands individual assessment of whether benefits justify burdens.
Valproate (Depakote): GABAergic Dampening
60%
G Enhancement
GABAergic mechanisms provide containment through increased inhibitory tone
40%
Δ² Suppression
Broad neural dampening reduces signal intensity
35%
Γ Impairment
Cognitive dulling commonly reported, reducing reflective capacity
Valproate's GABAergic mechanism creates G-enhancement through increased inhibitory neurotransmission—essentially turning up the brain's dampening systems. This provides containment but at cost: the same mechanism that stabilises also blunts. Cognitive effects are common, suggesting Γ impairment. The medication is more suppressive than lithium, making it less suitable for long-term Cl development.
Additional concerns include teratogenicity (absolute contraindication in pregnancy), hepatotoxicity risk, and frequent reports of subjective "flatness". Field translation: valproate forces G and suppresses Δ² but often at expense of vitality and reflective capacity. May be useful in acute mania (H > 1 states) but questionable for maintenance given Cl costs.
Lamotrigine (Lamictal): The Mood Floor
Lamotrigine's mechanism—glutamate modulation—creates a "floor" preventing H → 0 collapse without suppressing H > 1 capacity. This asymmetry is clinically significant: the medication prevents depressive crashes more than manic surges. Field translation: it stabilises the lower bound of consciousness dynamics without crushing the upper bound.
People often report feeling "like themselves" on lamotrigine—subjectively normal with reduced vulnerability to collapse states. This suggests relatively preserved Γ and Δ² functioning. The medication modulates rather than suppresses, supporting the system's own regulatory capacity rather than substituting for it.
Field Parameters
- G: ↑ Creates stability floor via glutamate modulation
- Γ: → Generally cognition-sparing; people report clarity
- Δ²: Modulated (prevents collapse more than excess)
The primary risk is severe rash (Stevens-Johnson syndrome), requiring slow titration. This creates a therapeutic delay—benefit doesn't emerge for weeks or months. However, if effective, lamotrigine may be among the most Cl-preserving mood stabilisers: it supports field stability without major cognitive, metabolic, or subjective costs.
Antidepressants
SSRIs: The Δ² Modulators
Selective serotonin reuptake inhibitors fundamentally alter Δ² sensitivity—the system's responsiveness to novel, threatening, or emotionally significant information. By increasing serotonergic tone, SSRIs reduce reactivity to both internal and external perturbations. This can relieve suffering but also creates "emotional blunting"—reduced access to the signal that Δ² carries.
The SSRI paradox: the same class of medications treats both depression (H → 0) and anxiety (often H oscillation from Δ² overwhelm). How can one mechanism address opposite presentations? Field explanation: both involve Δ² dysregulation. Depression may involve collapsed Δ² (nothing feels significant, no motivation to respond). Anxiety may involve excessive Δ² (everything feels threatening, constant hypervigilance). SSRIs modulate Δ² sensitivity regardless of direction—they normalise response to signal.
SSRI Field Dynamics
G: Variable Initial Effect
Can initially destabilise through activation syndrome—increased anxiety, agitation, sleep disruption. This typically resolves within weeks but represents early G destabilisation before eventual stabilisation.
Γ: Emotional Blunting Risk
Reduced emotional range may impair reflective capacity. If feelings are flattened, the system loses access to important internal signal. This can feel like relief initially but becomes problematic long-term.
Δ²: Reduced Reactivity
Both positive and negative valence signal is dampened. Reduced anxiety but also reduced joy, reduced distress but also reduced passion. The medication doesn't discriminate—it reduces sensitivity across the board.
The SSRI Dilemma: Signal Suppression Versus Signal Processing
SSRIs present a fundamental tension in psychopharmacological intervention. If Δ² carries important signal—trauma that needs processing, life circumstances demanding change, relational problems requiring attention—then suppressing reactivity to that signal delays necessary reckoning. The person feels "better" (less distressed) but the underlying field dynamics remain unaddressed.
Conversely, if Δ² is genuinely excessive relative to circumstances (anxiety disorder with catastrophic misinterpretation of neutral stimuli, panic disorder with physiological amplification loops), then reducing sensitivity may support functioning and create space for Cl development. The medication buys time and reduces suffering whilst capacity is built.
From a transformation programme perspective, SSRIs may arrest dissolution before reconstitution can occur—providing temporary relief while preventing the completion that would resolve the underlying inadequacy of current self-structure.
The clinical challenge: discerning when Δ² represents genuine dysregulation versus accurate response to genuinely difficult circumstances. SSRIs may be most appropriate when signal is disproportionate to stimulus, least appropriate when distress accurately reflects situations requiring change.
For Discontinuation Support
When the decision is made to taper SSRIs, see the Patient Companion App and Clinician Companion Tool for evidence-based withdrawal protocols that honor the complexity of this decision.
SNRIs: Adding Noradrenergic Modulation
Venlafaxine (Effexor)
- Serotonin reuptake inhibition at all doses
- Noradrenaline reuptake inhibition at higher doses
- More activating than SSRIs
- Withdrawal syndrome can be severe
- Dose-dependent blood pressure effects
Duloxetine (Cymbalta)
- Balanced serotonin/noradrenaline reuptake inhibition
- FDA-approved for pain conditions (fibromyalgia, neuropathy)
- May support arousal regulation better than pure SSRIs
- Nausea common initially
- Also difficult withdrawal profile
Field translation: Adding noradrenaline to serotonin modulation creates more complex field effects. Noradrenaline supports arousal, attention, and salience processing—potentially enhancing Γ whilst still dampening Δ². This may explain why SNRIs are sometimes effective for "atypical" depression with prominent fatigue, hypersomnia, and anhedonia (H → 0 with collapsed arousal). The noradrenergic component provides some lift that pure serotonergic agents lack.
Mirtazapine (Remeron): The Antihistamine Masquerading as Antidepressant
Primary Mechanism
H1 antihistamine blockade—profound sedation, increased appetite
Serotonergic Effects
5-HT2 and 5-HT3 receptor antagonism modulates which serotonin pathways are active
Field Translation
G forced through sedation; weight gain reflects metabolic disruption
Mirtazapine is often prescribed as a "sedating antidepressant" for people with insomnia and poor appetite. However, the mechanism reveals this is primarily antihistamine sedation with secondary antidepressant effects. The G-enhancement is forced (sedation) rather than earned (developed capacity). The appetite stimulation creates weight gain that becomes its own field disruption—metabolic syndrome, diabetes risk, reduced physical capacity.
Clinical critique: If the primary benefit is sleep and appetite, why not address those directly through sleep hygiene, somatic regulation, nutritional support? Mirtazapine creates chemical substitution for basic physiological regulation, with significant metabolic costs.
Bupropion (Wellbutrin): The Anti-SSRI
Field Parameters
- G: → to ↓ Can be activating, may disrupt sleep architecture
- Γ: ↑ Dopamine/noradrenaline support attention, motivation, executive function
- Δ²: → to ↑ Doesn't dampen signal; may increase activation and responsiveness
Bupropion represents a fundamentally different pharmacological strategy from serotonergic agents. Instead of dampening Δ², it supports Γ through dopaminergic and noradrenergic enhancement. This makes it useful for H → 0 states with collapsed motivation, anhedonia, and executive dysfunction—presentations where the problem is insufficient activation rather than excessive reactivity.
The mechanism explains the contraindication profile: bupropion can destabilise G through activation (insomnia, anxiety, agitation) and is contraindicated in eating disorders and seizure conditions. It lowers seizure threshold because it increases neural excitability—the opposite of dampening medications. Field translation: bupropion adds energy to the system, which helps if the problem is depletion but worsens instability if the problem is already excessive activation.
Bupropion Clinical Considerations
1
Ideal Candidates
H → 0 depression with prominent anhedonia, amotivation, cognitive slowing. SSRI-induced sexual dysfunction or emotional blunting. Nicotine cessation (dopaminergic support for addiction treatment).
2
Poor Candidates
Anxiety-predominant presentations, H > 1 or oscillating states, insomnia, eating disorders, seizure history. Anyone whose field is already destabilised by activation rather than depletion.
3
Cl Implications
By supporting Γ (attention, motivation) without suppressing Δ², bupropion may preserve capacity for engagement and processing. Less emotional blunting than SSRIs. However, if it destabilises G, the overall effect may still impede capacity development.
Anxiolytics
Benzodiazepines: Emergency G with Massive Cl Cost
Benzodiazepines represent the most rapid, powerful G-enhancement available in psychiatric pharmacology. Through GABAergic mechanisms, they create immediate containment—the overwhelmed nervous system is forcibly calmed within minutes. This makes them invaluable in acute crisis but catastrophic for long-term capacity development.
The field dynamics are stark: G↑↑↑ (profound, immediate), Γ↓ (amnesia, cognitive impairment), Δ²↓↓ (all signal blunted). The medication creates chemical containment whilst simultaneously impairing the reflective capacity needed to develop genuine self-regulation skills. Memory consolidation is disrupted—experiences aren't integrated, patterns aren't learned.
The Benzodiazepine Trap
1
Acute Relief
Panic attack, overwhelming anxiety, acute trauma response—benzodiazepine provides immediate containment when G has collapsed
2
Tolerance Development
Neuroadaptation occurs within weeks. Same dose produces less effect. Dose escalation begins.
3
Dependence Formation
System now requires medication to maintain baseline. Withdrawal creates rebound anxiety worse than original presentation.
4
Cl Bypass
Chemical G-forcing prevents learning to navigate anxiety. No capacity developed—only dependency created.
The ultimate psychiatric Faustian bargain: immediate relief in exchange for long-term incapacity. Every dose reinforces that anxiety is intolerable and requires chemical suppression. The person never learns that anxiety is survivable, that distress passes, that they possess internal resources for regulation.
Benzodiazepine Discontinuation Resource
For evidence-based benzodiazepine tapering guidance:
Based on the Ashton Manual and NICE NG215, this tool generates hyperbolic tapering schedules and provides withdrawal symptom awareness for collaborative clinical decision-making.
Field-Aligned Benzodiazepine Use
Appropriate Use
- Genuine acute crisis where G has completely collapsed
- Time-limited (days, not weeks or months)
- Explicit framing: "This is emergency stabilisation whilst we mobilise other resources"
- Concurrent mobilisation of relational, somatic, environmental G
- Taper planned from initiation
- Never as maintenance therapy
The question before prescribing: Is there any other way to provide containment? Can relational G be mobilised (support person present)? Can somatic G be engaged (breathwork, grounding techniques, physical activity)? Can environmental G be arranged (safe space, reduced demands)?
If benzodiazepines are genuinely necessary, their use must be framed as emergency measure—like a splint for a broken bone. The splint provides temporary support whilst healing occurs, but the goal is always to remove the splint and restore natural function. Chemical containment must never become chronic substitute for developed capacity.
Pregabalin (Lyrica): The "Gentler" Dependency Creator
70%
G Enhancement
GABAergic-adjacent effects via calcium channel modulation create substantial containment
50%
Δ² Suppression
Broad anxiolysis dampens signal processing across contexts
40%
Γ Impairment
Cognitive effects including memory problems, reduced attention, subjective "fogginess"
Pregabalin is often positioned as "safer than benzodiazepines"—less acute cognitive impairment, different receptor mechanism, approved for various pain and anxiety conditions. However, field analysis reveals similar dynamics: G-forcing through neural dampening, Δ² suppression, Γ impairment, and significant dependence potential.
The "gentler" framing is dangerous because it facilitates long-term prescribing. People are maintained on pregabalin for months or years under the assumption it's a benign intervention. Meanwhile, the same Cl-bypass occurs: chemical containment substitutes for capacity development, withdrawal becomes difficult, underlying field dynamics remain unaddressed.
Stimulants
ADHD Medications: Capacity-Revealing, Not Capacity-Substituting
Stimulant medications for ADHD represent a fundamentally different pharmacological category within field-based analysis. Unlike suppressant medications (antipsychotics, benzodiazepines), stimulants enhance Γ—the system's capacity for reflection, attention direction, and executive function. They don't substitute for capacity; they reveal capacity that was always present but inaccessible due to neurotype-ecosystem mismatch.
The paradoxical calming effect in ADHD makes sense through field theory: stimulants enhance Γ, which improves self-regulation, which stabilises G. The person becomes calmer not through sedation but through improved capacity to direct attention, inhibit impulses, and maintain executive control. This is the opposite of benzodiazepine "calmness"—it's increased capability rather than decreased arousal.
Stimulant Field Dynamics
G: Ground
→ to ↑ Paradoxical calming in ADHD brains. The improved executive function allows better self-regulation, which stabilises the container.
Γ: Reflection
↑↑ Enhanced attention, improved executive function, better working memory. The capacity to observe, plan, and direct cognition is markedly improved.
Δ²: Novelty
Modulated (filtered rather than suppressed). Improved signal-to-noise ratio. Relevant information can be attended to; irrelevant stimuli more easily ignored.
The Neurotype-Ecosystem Mismatch
The fundamental insight: ADHD represents cognitive architecture designed for one type of environment (high novelty, rapid context-switching, hunting-gathering) attempting to function in a radically different environment (sustained attention, delayed gratification, industrial-bureaucratic demands). The "disorder" is the mismatch, not the brain.
Stimulant medications don't fix a broken brain—they provide pharmacological accommodation to an ill-fitting world. This is genuinely a "sad situation": we've created educational and occupational ecosystems so poorly matched to neurodivergent cognition that chemical intervention becomes necessary for basic functioning.
However, the accommodation is different in kind from suppressive medications. Stimulants improve the system's capacity to navigate existing demands. They enhance rather than impair. The person on appropriate stimulant medication often reports feeling "more like myself" rather than dulled or flattened.
The Revelation That Persists
With Suppressant Medications
Discontinuation reveals unchanged underlying dynamics. The anxiety returns, the mood destabilises, the "symptoms" re-emerge. Nothing was learned—only temporarily dampened.
The medication substituted for capacity rather than supporting its development. Ce = Cn - Cl remains unchanged because Cl was never enhanced.
With ADHD Stimulants
Some individuals find that capacities revealed during medication use remain partially accessible after discontinuation. The medication showed what they were capable of—strategies learned, insights gained, confidence developed.
The revelation persists because genuine capacity was accessed, not chemically created. The medication cleared interference rather than creating something that wasn't there.
Critical Distinction: This doesn't mean all ADHD medication can be discontinued. For many, the neurotype-ecosystem mismatch is severe enough that ongoing pharmacological support is necessary. But the knowledge and strategies gained whilst medicated often transfer to unmedicated states—evidence of capacity enhancement rather than mere suppression.
The Suppression Problem
This distinction between suppression and resolution is explored in depth in Critical Insights into Contemporary Psychiatric Practice, which examines Moncrieff's drug-centred model: medications create altered states rather than correcting deficits. The field framework translates this insight into practical clinical reasoning.
Why ADHD Medications Are Different
01
Signal-to-Noise Enhancement
Stimulants improve the brain's ability to discriminate relevant from irrelevant information. This is filtering, not suppression—important signal becomes more accessible.
02
Executive Function Support
Working memory, planning, impulse inhibition—the cognitive tools for self-regulation—become more reliably available. This supports autonomous navigation of challenges.
03
Capacity Revelation
The medication doesn't create abilities that don't exist; it clears the interference preventing access to existing capabilities. This is fundamentally different from chemical suppression.
04
Preserved Vitality
Unlike antipsychotics or benzodiazepines, stimulants typically don't create subjective dulling. People report feeling more present, more capable, more themselves—not flattened or numbed.
Field framework conclusion: ADHD stimulants are the closest thing to genuinely field-aligned pharmacology in the current psychiatric toolkit. They enhance Γ, support G through improved self-regulation, and modulate rather than suppress Δ². They accommodate neurotype-ecosystem mismatch whilst preserving and often enhancing the person's capacity to navigate their own consciousness.
Pause: Mapping the Medications
Before moving to clinical application, pause to integrate: What patterns do you notice? Most conventional medications suppress rather than resolve. The exceptions—stimulants and psychedelics—work through fundamentally different mechanisms. This distinction matters for how we think about prescribing and deprescribing.
Emerging Paradigm
Psychedelics: Inverting the Psychiatric Model
Psychedelic substances represent a fundamental inversion of conventional psychiatric pharmacology. Where standard medications suppress Δ² and force G, psychedelics amplify Δ², temporarily dissolve G, and massively enhance Γ during the acute experience. This creates conditions for profound recognition and integration—but outcomes depend entirely on field context.
The therapeutic mechanism isn't the molecule itself—it's the state of consciousness the molecule enables, combined with the container (set and setting) within which that state unfolds. Same pharmacology produces breakthrough or breakdown depending on whether adequate external G supports the temporary dissolution of internal G.
Psilocybin Field Dynamics
Acute G Dissolution
Ego boundaries become permeable, self-world distinctions blur, ordinary containment structures temporarily collapse. This is controlled dissolution, not pathological fragmentation—if container is adequate.
Δ² Amplification
Signal intensity increases dramatically. Emotional material, suppressed memories, existential insights—all become vividly present. Filtering is reduced; raw experience flows through.
Γ Enhancement
Paradoxically, whilst ordinary ego dissolves, reflective capacity can dramatically increase. The capacity to observe, recognise patterns, gain insight is often profoundly enhanced.
Post-Integration
If experience is adequately supported and processed, G can reorganise at higher coherence. Insights integrate, patterns shift, capacity expands. This is the opposite of suppression—it's transformation.
Why Mystical Experience Predicts Outcome
Research shows mystical experience intensity explains 54% of variance in depression reduction—not the pharmacology itself, but the transformation experience. This supports the transformation programme hypothesis: therapeutic benefit derives from completing the dissolution → reconstitution sequence with adequate container and meaning-making support.
Deeper Exploration
For comprehensive exploration of psilocybin's effects on creativity, consciousness, and the intersection with neuroscience and mythology, see: https://muse-in-mushroom-6zxl47q.gamma.site/
For understanding how psychedelic phenomenology maps onto field dynamics (G, Γ, Δ², H) and psi phenomena, see: https://recognition-field-dynami-90594gv.gamma.site/
These resources bridge the clinical psychopharmacology with the deeper phenomenology and consciousness theory underlying the field framework.
Why Outcomes Vary: The Set and Setting Imperative
The psychedelic paradox: same dose of same substance can produce life-changing therapeutic breakthrough or destabilising psychological crisis. The difference isn't the pharmacology—it's the field conditions.
Adequate External G
- Trained therapeutic presence
- Safe, comfortable physical environment
- Clear intention and preparation
- Integration support afterwards
- Relational holding of the experience
Result: Temporary internal G dissolution can be tolerated because external G is robust. Profound material emerges and can be integrated.
Inadequate External G
- Unsupported, solo experience
- Chaotic or threatening environment
- No preparation or framing
- No integration pathway
- Relational isolation
Result: Temporary internal G dissolution becomes overwhelming. Profound material emerges but cannot be integrated—may fragment rather than transform.
Psychedelics and Consciousness Literacy
Psychedelic experiences potentially support Cl development in ways conventional medications cannot. By temporarily dissolving ordinary frameworks and amplifying reflective capacity, they create opportunities to recognise patterns, access suppressed material, and reorganise self-understanding at fundamental levels.
However, this is profoundly different from taking a daily medication. The therapeutic mechanism is the journey through altered states, not chronic receptor modulation. The medicine is the experience itself—the dissolution, the encounter with amplified material, the subsequent integration. The molecule creates conditions; the person (with support) does the work.
Field framework understanding: Psychedelics don't treat disorders—they create temporary field conditions conducive to transformation. Whether transformation occurs depends on preparation, container quality, integration support, and the person's capacity to metabolise profound experience. This is the opposite of "take this pill for your condition" medicine.
Ketamine: Brief Field Reorganisation
1
Acute Dissociation
NMDA receptor blockade creates temporary dissociative state. Self-world boundaries alter, ordinary consciousness dissolves briefly.
2
H < 0 Window
During dissociation, field coherence temporarily dissolves (H < 0). This may allow system reset—rigid patterns briefly release.
3
Rapid Return
Unlike psilocybin's hours-long journey, ketamine's effects are brief. Ordinary consciousness returns within hours.
4
Transient Benefit
Rapid antidepressant effect reported, but often transient. Without integration support, field returns to baseline because no Cl developed.
Ketamine's therapeutic use reveals a critical limitation: brief pharmacological field alteration without integration support produces transient benefit. The system resets temporarily but returns to habitual patterns because the underlying dynamics (Cn, Cl, Ce) haven't changed. This is why ketamine often requires repeated dosing—it's providing temporary relief rather than supporting transformation.
Clinical Deep Dive
For comprehensive clinical review of ketamine-assisted psychotherapy including evidence base, protocols, consciousness-centered vs medical models, and practical implementation: https://ketamine-assistance-2s8cuwd.gamma.site/
This resource provides the clinical depth and practical guidance for implementing ketamine work within the field-based framework, distinguishing transformative protocols from symptom-suppression approaches.
Integration: From Theory to Practice
This card provides transition space between medication mapping and clinical framework.
You've now encountered:
- The epistemological critique (why diagnostic categories fail)
- The biological substrate (neuroinflammation disrupts field coherence)
- The cognitive architecture (wild-type minds are vulnerable)
- The transformation programme (what's actually happening during crisis)
- The field mechanics (G, Γ, Δ², H as organizing principles)
- The medication mappings (what drugs actually do to these dynamics)
The question now becomes: How do we apply this understanding in clinical practice?
Reflection Prompt
Take a moment before proceeding. Does the framework make sense? Can you see how medications modulate field parameters rather than correcting deficits? The clinical section ahead will show how to use this lens for prescribing and deprescribing decisions.
Clinical Framework
Decision Framework: When to Prescribe, When to Withhold
Field-based prescribing demands a fundamentally different decision process from disease-centred approaches. Rather than matching drugs to diagnoses, we must carefully assess field dynamics, consider non-pharmacological alternatives, evaluate capacity-building implications, and plan exit strategies before initiation.
This requires epistemological honesty about what we're doing and genuine consideration of whether chemical intervention supports or impedes the person's development of navigational capacity. Sometimes the most therapeutic choice is pharmaceutical restraint.
Questions Before Prescribing
1
What Field Parameter Is Destabilised?
Is G collapsing (loss of containment, sleep disruption, autonomic dysregulation)? Is Γ fragmented (impaired reflection, attention problems, loss of narrative coherence)? Is Δ² overwhelming (trauma activation, excessive novelty, unmanageable stress) or collapsed (anhedonia, loss of significance)?
Precise phenomenological mapping is essential. "Anxiety" or "depression" are diagnostically useless—we need to understand the actual consciousness dynamics.
2
Is Medication the Only Way to Address This Parameter?
G can be enhanced: Relationally (therapeutic alliance, support networks), somatically (breathwork, movement, touch), environmentally (housing stability, reduced demands, routine)
Γ can be supported: Through mirroring (therapy), structured reflection (journaling, meditation), psychoeducation, skills training
Δ² can be modulated: Through pacing (reducing overwhelm), titrated exposure (gradually building tolerance), stress reduction, trauma processing
3
Will This Medication Support or Impede Cl Development?
Suppressant medications (antipsychotics, benzodiazepines, high-dose antidepressants) tend to impede—they substitute chemical intervention for learned capacity. Capacity-enhancing medications (stimulants for ADHD, possibly lithium/lamotrigine) may support. Short-term stabilisation can support if explicitly time-limited with concrete taper plan.
4
What Is the Exit Strategy?
How will we know medication is no longer needed? What Cl markers would indicate readiness to taper? What non-pharmacological supports are we putting in place that medication currently substitutes for? If we can't answer these questions, we're likely creating dependency rather than providing bridge.
Field-Based Reasoning in Action
This card demonstrates how to apply the framework through a realistic clinical scenario.
Case Presentation:
"Sarah, 28, presents with 'treatment-resistant depression.' She's tried four SSRIs, two SNRIs, and augmentation with quetiapine 50mg. She reports feeling 'numb and disconnected' but still experiences waves of intense anxiety and self-criticism. Sleep is poor. She works in a demanding job with little support. Recent relationship ended."
Disease-Centred Reasoning:
"Inadequate response suggests need for dose escalation or medication switch. Consider adding mood stabilizer. Quetiapine could be increased to 100-150mg for better effect. Perhaps try MAOI or ECT if this fails."
Field-Based Reasoning:
"Current medications suppress Δ² (SSRIs) and force G through sedation (quetiapine). Result: emotional blunting (suppressed signal) without addressing underlying dynamics.
Field assessment:
- G: Collapsed (poor sleep, no external support, demanding environment)
- Γ: Impaired by emotional numbing, self-criticism suggests harsh internal observer
- Δ²: Suppressed by medications, but anxiety suggests unprocessed signal
- H: Low coherence—system is suppressed but not integrated
The 'treatment resistance' may be iatrogenic—medications preventing the processing that would lead to resolution.
Alternative approach:
- Strengthen external G first (sleep, support, reduce demands if possible)
- Consider careful SSRI reduction to allow signal processing
- Develop Γ through therapy (what is the anxiety trying to communicate?)
- Address Δ² through processing rather than suppression
- Build capacity rather than indefinitely suppressing"
The Distinction:
"Disease-centred: escalate suppression. Field-based: build capacity and allow processing. Different paradigms, different outcomes."
Clinical Vignettes: Field-Based Reasoning
The following vignettes are invitations to explore, not prescriptions to follow. Each presents a clinical moment where field-based reasoning might shift our understanding. There are no 'correct answers'—only opportunities to practice seeing through a different lens.
Vignette
The Anxious Student
Marcus, 19, first year university. Diagnosed ADHD at 16, on methylphenidate 54mg. Now presenting with increasing anxiety—racing thoughts, insomnia, panic attacks before exams. His GP added sertraline 50mg six weeks ago. Anxiety unchanged, now also experiencing emotional flatness and sexual dysfunction.
Field Assessment:
- G: Destabilised (sleep disruption, autonomic arousal)
- Γ: Hyperactive but ungrounded (racing thoughts without integration)
- Δ²: High (academic demands, social transition, stimulant-induced arousal)
- H: Oscillating between anxious activation and flat suppression
- Ce/Cn/Cl: High Cl (environmental demands + medication effects), Cn not addressed, Ce collapsing
Two Approaches:
Disease-Centred:
- Increase sertraline to 100mg
- Add propranolol for physical anxiety symptoms
- Consider switching to venlafaxine for "treatment-resistant anxiety"
- Maintain stimulant dose
Field-Based:
- Recognize stimulant may be amplifying Δ² beyond integration capacity
- SSRI dampening Δ² but not addressing root dynamics
- Question: Is this anxiety or stimulant-induced hyperarousal?
- Consider: Reduce methylphenidate, support Cn through sleep hygiene, breath regulation, academic accommodations
- Build capacity before adding more suppression
Gentle Questions for Reflection:
- What might Marcus's anxiety be signaling about his current field conditions?
- How might the stimulant be interacting with his transition to university?
- What would "building capacity" look like in his specific situation?
Vignette
The Sleepless Professional
Aisha, 42, senior manager. Prescribed quetiapine 25mg for insomnia by her GP two years ago. Now on 150mg nightly. Reports sleeping better but feels "foggy" during the day, gained 15kg, pre-diabetic on recent bloods. Wants to stop quetiapine but terrified of insomnia returning. Previous attempt to reduce led to severe rebound insomnia and panic.
Field Assessment:
- G: Artificially forced through sedation, not genuine containment
- Γ: Suppressed (cognitive dulling, reduced meta-cognitive capacity)
- Δ²: Unknown—never addressed, only suppressed
- H: Maintained near zero through pharmaceutical constraint
- Ce/Cn/Cl: Cn never developed (no sleep skills, unaddressed stress), Cl suppressed but present, Ce dependent on medication
Two Approaches:
Disease-Centred:
- "You have chronic insomnia requiring long-term treatment"
- Continue quetiapine, add metformin for metabolic effects
- If wants to reduce: switch to mirtazapine or trazodone
- Frame any sleep difficulty as "relapse of insomnia disorder"
Field-Based:
- Recognize quetiapine created dependency, not treated insomnia
- Rebound insomnia is withdrawal, not disease return
- Original insomnia likely signaled unaddressed Cl (work stress, life circumstances)
- Taper must be slow (10% reductions) while building Cn
- Develop sleep capacity: sleep hygiene, breath regulation, stress management, possibly therapy
- Address root Cl: what was the insomnia signaling two years ago?
Gentle Questions for Reflection:
- What might Aisha's original insomnia have been communicating?
- How has quetiapine prevented her from developing natural sleep capacity?
- What would a "capacity-building" approach to sleep look like?
- How might we support her through the fear of withdrawal?
Vignette
The Grieving Parent
David, 55, lost his teenage daughter in a car accident four months ago. His GP prescribed sertraline 50mg at six weeks post-loss when he was "still crying daily" and "not functioning at work." Now on 100mg. Reports feeling "numb" rather than sad, disconnected from his wife, unable to feel joy about anything. Describes himself as "going through the motions."
Field Assessment:
- G: Collapsed by trauma, not restored by medication
- Γ: Suppressed—unable to process grief, disconnected from emotional experience
- Δ²: Massive (traumatic loss) but dampened rather than integrated
- H: Near zero—emotional flatness, disconnection
- Ce/Cn/Cl: Enormous Cl (grief, trauma), Cn overwhelmed, SSRI suppressing Cl rather than supporting integration
Two Approaches:
Disease-Centred:
- "You have major depressive disorder triggered by bereavement"
- Continue/increase SSRI for "treatment of depression"
- Add mirtazapine if sleep remains poor
- Consider augmentation with antipsychotic if no improvement
- Frame grief as pathological depression requiring treatment
Field-Based:
- Recognize grief as natural process requiring integration, not suppression
- SSRI dampening Δ² (grief signal) preventing necessary processing
- Numbness is medication effect, not healing
- Question: Is this depression or medicated grief?
- Consider: Slow SSRI taper while building Cn through grief therapy, support groups, meaning-making
- Create conditions for grief to complete its natural trajectory
- Distinguish between complicated grief (needing support) and normal grief (needing space)
Gentle Questions for Reflection:
- What is the difference between treating depression and supporting grief?
- How might David's numbness relate to the SSRI rather than healing?
- What would "creating space for grief" look like in practice?
- When does grief need support versus when does it need medication?
Vignette
The Creative Surge
Maya, 34, artist. History of "bipolar II" diagnosis. Experiencing creative surge—painting 12 hours daily, new ideas flowing, feels "finally alive" after years of feeling "dampened." Sleeping 4-5 hours, feels rested. Husband concerned she's "getting manic again" and wants her to see psychiatrist. Previous manic episode at 25 led to hospitalization, but this feels different to her—focused, productive, joyful rather than chaotic.
Field Assessment:
- G: Adequate (still eating, maintaining relationships, coherent)
- Γ: Enhanced (high insight, self-awareness, able to reflect)
- Δ²: High but integrating (creative flow, not overwhelming)
- H: >1 (amplified but not runaway)
- Ce/Cn/Cl: High Ce (expressing capacity), adequate Cn (can contain the energy), manageable Cl
Two Approaches:
Disease-Centred:
- "This is hypomania requiring immediate treatment"
- Restart mood stabilizer (lithium or valproate)
- Add antipsychotic if doesn't respond quickly
- Frame creativity as symptom of illness
- Prevent escalation to "full mania"
- Suppress the surge to prevent "crash"
Field-Based:
- Distinguish between creative flow (H>1 with adequate Cn) and mania (H>1 with collapsing Cn)
- Assess: Is Γ intact? Can she reflect on her state?
- Monitor: Is G holding? Sleep, nutrition, relationships maintained?
- Question: Is this pathology or capacity expression?
- Support rather than suppress: ensure adequate sleep, nutrition, grounding practices
- Watchful waiting with clear markers for intervention
- Recognize that suppressing this might suppress her creative capacity long-term
Gentle Questions for Reflection:
- How do we distinguish creative flow from hypomania?
- What markers would indicate this is becoming problematic?
- How might premature intervention affect Maya's creative capacity?
- What would "supporting without suppressing" look like here?
Vignette
The Veteran's Polypharmacy
James, 48, Iraq veteran. Diagnosed PTSD, depression, anxiety. Current medications: sertraline 200mg, quetiapine 300mg, pregabalin 600mg, propranolol 80mg. On this regime for 3 years. Reports feeling "stable but not alive"—no nightmares, but also no joy, no motivation, significant weight gain, pre-diabetic. Sleeps 10-12 hours daily. Wants to "feel something again" but terrified of symptoms returning.
Field Assessment:
- G: Artificially forced through multiple sedating agents
- Γ: Severely suppressed (cognitive fog, emotional blunting)
- Δ²: Completely dampened (trauma signal suppressed, not processed)
- H: Near zero—pharmaceutical flatness
- Ce/Cn/Cl: Massive Cl (unprocessed trauma), Cn never developed, Ce minimal despite medication "stability"
Two Approaches:
Disease-Centred:
- "You have severe, chronic mental illness requiring lifelong treatment"
- Maintain current regime—"if it's not broken, don't fix it"
- Add stimulant for cognitive symptoms
- Add metformin for metabolic effects
- Frame any distress as "breakthrough symptoms" requiring more medication
- Discourage reduction attempts as "too risky"
Field-Based:
- Recognize polypharmacy is suppressing rather than healing
- Trauma remains unprocessed, only dampened
- Current state is medication effect, not wellness
- Slow, careful deprescribing while building Cn through trauma therapy
- One medication at a time, 10% reductions
- Develop capacity: trauma-informed therapy, peer support, meaning-making, physical health
- Distinguish withdrawal from symptom return
- Goal: process trauma rather than suppress it indefinitely
Gentle Questions for Reflection:
- What is the difference between "stable" and "well"?
- How has polypharmacy prevented James from processing his trauma?
- What would trauma integration look like versus trauma suppression?
- How might we support him through the fear of feeling again?
- What does "building capacity" mean for someone with complex PTSD?
Vignette
The Benzodiazepine Years
Linda, 62, on diazepam 10mg twice daily for 15 years. Originally prescribed for "panic disorder" following divorce. Now reports no panic attacks but feels "can't function without it"—takes morning dose before leaving house, afternoon dose before any social situation. Tried to stop once, experienced severe anxiety, tremor, insomnia, felt "like I was dying." GP says "you just need it" and continues prescribing. Cognitive decline noted by family, multiple falls, memory problems.
Field Assessment:
- G: Completely dependent on external chemical containment
- Γ: Impaired (benzodiazepine-induced cognitive effects)
- Δ²: Unknown—never learned to manage without medication
- H: Artificially maintained through chronic GABAergic enhancement
- Ce/Cn/Cl: Cn never developed (no anxiety management skills), Cl unknown, Ce entirely medication-dependent
Two Approaches:
Disease-Centred:
- "You have chronic anxiety disorder requiring long-term treatment"
- Continue diazepam indefinitely
- Attribute cognitive decline to "aging" or "depression"
- Frame withdrawal attempt as proof of need for medication
- "If it works, why change it?"
Field-Based:
- Recognize 15 years of benzodiazepines has created profound dependency
- Cognitive decline likely medication effect, not aging
- Original panic disorder may have resolved years ago
- Withdrawal will be difficult but possible with proper support
- Very slow taper (5-10% reductions every 2-4 weeks)
- Build Cn while tapering: anxiety management skills, therapy, breath work, support group
- Distinguish withdrawal anxiety from original anxiety
- Goal: develop natural capacity for anxiety regulation
Gentle Questions for Reflection:
- How do we distinguish medication dependency from ongoing illness?
- What might Linda's life look like without benzodiazepines?
- How has 15 years of medication prevented capacity development?
- What support would she need to attempt withdrawal safely?
- How do we address the fear that's been reinforced for 15 years?
Vignette
The First Episode
Kai, 22, university student. First psychotic episode—hearing voices commenting on his actions, believing his thoughts are being broadcast, feeling watched. Brought to emergency by friends after three days without sleep, talking rapidly about "seeing the patterns in everything." Frightened but also describes feeling "more awake than ever before." No previous psychiatric history. Family history of "schizophrenia" (grandfather, hospitalized 1970s).
Field Assessment:
- G: Collapsed (no sleep, overwhelmed, disorganized)
- Γ: Fragmented but present (can reflect on experience, recognizes something unusual happening)
- Δ²: Overwhelming (massive pattern recognition, sensory flooding)
- H: <0 (dissolution, boundary loss)
- Ce/Cn/Cl: Enormous Cl (psychotic process), Cn overwhelmed, Ce collapsed
Two Approaches:
Disease-Centred:
- "You have schizophrenia, a lifelong brain disease"
- Immediate antipsychotic (risperidone or olanzapine)
- Frame as medical emergency requiring rapid suppression
- Expect lifelong medication
- Emphasize family history as genetic inevitability
- Suppress the experience as quickly as possible
Field-Based:
- Recognize this as acute crisis requiring containment, not necessarily chronic illness
- Immediate priority: restore G (sleep, safety, calm environment)
- Consider: Is this first episode or transformation programme activation?
- Provide intensive relational containment (Open Dialogue approach if available)
- Medication as temporary support while building Cn, not automatic lifelong treatment
- Allow process to complete with adequate support
- Assess after acute phase: was this one-time crisis or ongoing vulnerability?
- Family history doesn't determine individual trajectory
Gentle Questions for Reflection:
- How do we distinguish first episode psychosis from transformation programme?
- What role does immediate antipsychotic play versus intensive relational support?
- How might our initial framing affect Kai's long-term trajectory?
- What would "supporting the process to completion" look like?
- When is medication essential versus when might it interrupt natural resolution?
Vignette
The Chronic Pain Spiral
Elena, 51, chronic back pain following car accident 5 years ago. Started on pregabalin 75mg, now on 600mg daily. Also taking tramadol, amitriptyline, and occasional diazepam. Pain unchanged. Reports feeling "disconnected," memory problems, weight gain, depression. Wants to reduce medications but every attempt leads to severe anxiety, insomnia, and pain flare. Feels "trapped"—pain without medication unbearable, life on medication barely tolerable.
Field Assessment:
- G: Dependent on multiple sedating medications
- Γ: Suppressed (cognitive fog, emotional blunting)
- Δ²: Pain signal dampened but not addressed
- H: Near zero—pharmaceutical suppression
- Ce/Cn/Cl: High Cl (chronic pain, medication effects), Cn never developed (no pain management skills), Ce minimal
Two Approaches:
Disease-Centred:
- "You have chronic pain syndrome requiring long-term medication"
- Maintain current regime or escalate doses
- Add antidepressant for "pain-related depression"
- Frame reduction attempts as proof of medication necessity
- Consider opioid escalation if pregabalin insufficient
- Pain management as pharmaceutical problem
Field-Based:
- Recognize medication dependency separate from pain condition
- Withdrawal symptoms (anxiety, insomnia) distinct from pain
- Current regime suppressing without healing
- Very slow taper (one medication at a time, 10% reductions)
- Build Cn while tapering: pain psychology, physiotherapy, mindfulness, pacing
- Address neuroplastic pain versus structural pain
- Develop capacity for pain management beyond medication
- Recognize that some pain may persist but quality of life can improve
Gentle Questions for Reflection:
- How do we distinguish pain from medication withdrawal?
- What is the difference between pain suppression and pain management?
- How has medication dependency complicated Elena's pain condition?
- What would "building capacity" for chronic pain look like?
- How might reducing medication paradoxically improve quality of life?
The "It Doesn't Work" Protocol
When a patient reports medication "not working", the disease-centred reflex is dose escalation or medication switching. Field-based practice demands more careful analysis of what "working" means and whether pharmacological intensification addresses actual dynamics.
01
Define "Working"
What outcome was expected? Symptom suppression? Functional improvement? Felt sense of capacity? Often "not working" means "symptoms still present" when symptoms may accurately reflect unchanged life circumstances or underdeveloped capacity.
02
Assess Field Parameters
Has G actually stabilised, or are we just sedating? Is Γ functional, or have we blunted reflection? Is Δ² manageable, or have we suppressed important signal? Medication may be "working" pharmacologically whilst failing to support genuine capacity.
03
Consider Ce = Cn - Cl
Is the problem high Cn (genuinely difficult life circumstances, inescapable complexity) that no medication can address? Is Cl underdeveloped (limited coping skills, poor self-regulation, inadequate support)? Chemical intervention cannot solve social, relational, or economic problems.
04
Before Dose Increase
Will more medication build capacity or deepen suppression? Is there a non-pharmacological intervention that addresses the actual destabilised parameter? Sometimes "treatment resistance" is the system correctly refusing interventions that don't match actual needs.
The Deprescribing Framework
Deprescribing—the process of reducing or discontinuing medications—requires as much skill and attention as prescribing. Yet conventional psychiatric practice often neglects exit planning entirely, creating indefinite maintenance regimes that substitute for capacity development.
From a transformation programme perspective, deprescribing is not simply medication removal—it's creating conditions for completion of processes that were interrupted. The person may need to revisit dissolution states that were pharmacologically suppressed, this time with adequate container and integration support.
Field-based practice demands deprescribing be considered from the moment of prescribing. Every medication initiation should include clear criteria for discontinuation and concrete plans for building the capacities that medication currently substitutes for.
Practical Deprescribing Resources
For patients navigating antidepressant discontinuation:
Patient Companion App - Spiral Withdrawal Companion with assessment, tracking, and advocacy tools
Patient Companion App - Spiral Withdrawal Companion with assessment, tracking, and advocacy tools
For clinicians supporting antidepressant tapering:
Clinician Companion Tool - Evidence-based hyperbolic tapering calculator and communication templates
Clinician Companion Tool - Evidence-based hyperbolic tapering calculator and communication templates
For benzodiazepine reduction:
Benzodiazepine Reduction Guide - Ashton Manual-based tapering framework
Benzodiazepine Reduction Guide - Ashton Manual-based tapering framework
These tools apply Spiral Psychiatry principles to the practical mechanics of medication discontinuation, translating field-based understanding into actionable clinical protocols.
Supporting Emotional Intensity During Withdrawal
Emotional intensity often increases during medication reduction—not because the medication was "working," but because suppressed signals are returning to awareness. This requires active support, not just slower tapering.
For comprehensive guidance on working with emotional intensity during withdrawal and beyond:
Emotional Intensity Toolkit: https://claude.ai/public/artifacts/bbe3bd84-b0b0-48fe-b99b-0cdba6cf1457
This interactive tool provides:
- Patient-facing: Understanding emotional intensity through G/Γ/Δ² framework, crisis planning, phase-based recovery approach
- Clinician-facing: ICD-11 dimensional formulation, evidence-based therapy alignment (DBT, MBT, Schema Therapy), deprescribing considerations
- Team-facing: Parallel process recognition, consistency protocols, splitting dynamics management
The toolkit reframes "personality disorder" as developmental gaps in containment, reflection, and sensitivity regulation—capacities that can be built during and after medication reduction.
Readiness Markers for Taper
External G Established
Stable housing, reliable relationships, consistent routine. Environmental container is robust enough to hold expected perturbations during taper.
Γ Functional
Person can reflect on their own states, recognise patterns, understand triggers. Meta-cognitive capacity is sufficiently developed to navigate challenges.
Δ² Manageable
Life stressors have reduced, or coping capacity has improved such that Δ² is within tolerance. Signal intensity matches integration capability.
Cl Indicators Present
Person has navigated challenges without requiring dose increases. Evidence of developed capacity: managed setbacks, used skills, sought support appropriately, maintained functioning during stress.
Taper Principles
Go Slowly
10% reductions, not 50%. The brain adapted to medication presence over months or years; it needs time to readapt. Rapid tapers create destabilisation that gets misinterpreted as "need" for medication.
Hyperbolic tapering (reducing by percentage of current dose rather than fixed amount) accounts for non-linear neuroadaptation.
Increase Support
Enhanced relational and therapeutic G during taper. More frequent check-ins, clearer support plans, explicit permission to pause or reverse if needed.
The external container strengthens as chemical container reduces. This prevents field collapse during transition.
Informed Understanding
Person understands withdrawal phenomena versus genuine relapse. Transient sleep disruption, mood fluctuation, anxiety during taper are expected neuroadaptation—not necessarily indication to resume medication.
Reversibility
Pause or reverse taper if destabilisation exceeds integration capacity. This isn't failure—it's appropriate responsiveness to field dynamics. Perhaps external G needs strengthening first, or Cl development requires more time.
The Withdrawal ≠ Relapse Distinction
Conflating withdrawal with relapse is one of the most pernicious errors in psychiatric practice. It leads to unnecessary long-term prescribing, reinforces patient beliefs about medication necessity, and prevents genuine assessment of whether ongoing pharmacological intervention is required.
Withdrawal
Time-limited destabilisation from neuroadaptation reversal. The brain adapted to medication presence (receptor downregulation, neurotransmitter compensation). Removal creates temporary imbalance whilst system readapts to unmedicated state.
Characteristics: Onset shortly after dose reduction, peaks within days to weeks, gradually resolves even without medication resumption, symptoms may differ from original presentation.
Relapse
Return of underlying field dynamics that were suppressed rather than resolved. The original consciousness dynamics re-emerge because Cn hasn't changed and Cl wasn't developed whilst medicated.
Characteristics: May emerge after withdrawal period ends, resembles original presentation, persists or worsens without intervention, indicates unchanged underlying field dynamics.
Field Framework Reveals the Real Problem
Much of what gets labelled "relapse" is actually the system encountering unchanged Cn with medication-suppressed Cl. The person's life circumstances haven't improved, their coping skills weren't developed whilst medicated, their relational supports remain inadequate—and now the chemical suppression is removed.
The solution isn't re-medication; it's building Cl with adequate support. This might mean:
- Addressing life circumstances (Cn reduction): housing, employment, relationships, safety
- Developing skills (Cl enhancement): emotion regulation, distress tolerance, interpersonal effectiveness
- Strengthening supports (external G): therapy, community, practical assistance
- Processing unresolved material (Δ² integration): trauma work, grief, existential reckoning
Sometimes medication is genuinely necessary long-term. But this should be determined through careful taper attempts with robust support, not assumed from withdrawal phenomena or rapid relapse after inadequately supported discontinuation.
Paradigm Shift
Toward Liberation Pharmacology
The field framework doesn't reject psychiatric medication—it contextualises pharmacology within a larger understanding of consciousness dynamics and human capacity. Medications become tools for temporary field modulation in service of capacity development, not indefinite suppressants that substitute for learning to navigate one's own consciousness.
This represents genuine paradigm shift: from viewing medications as treatments for brain diseases to understanding them as interventions in complex consciousness fields. From asking "Which drug treats this diagnosis?" to "What does this consciousness need, and will pharmacological intervention support or impede that need?"
Liberation pharmacology means using medications, when necessary, to create conditions for growth rather than chronic dependency. It means honest acknowledgement of what medications can and cannot do. It means planning exit strategies from initiation. It means developing the capacities that medications temporarily substitute for.
Summary: The Paradigm Shift
1
From Disease-Centred
"Which medication treats this diagnosis?" Medications correct chemical imbalances, treat disorders, require indefinite maintenance. Side effects are unfortunate necessities. Non-response indicates treatment resistance requiring medication intensification.
2
To Field-Centred
"What field parameter is destabilised, and will chemical modulation support or impede capacity development?" Medications temporarily modulate consciousness dynamics. They may support or impede navigation capacity. All effects are integral—there are no "side" effects, only effects we've chosen to deprioritise.
3
To Liberation-Oriented
"What does this consciousness need, and how do we support its development?" Medications are time-limited bridges whilst building capacity. Exit planning begins at initiation. Non-pharmacological interventions are prioritised. The goal is autonomous navigation, not pharmaceutical dependency.
This framework remains work in progress—developed through clinical observation, mechanistic reasoning, and field-based consciousness theory. It inherits all the epistemological problems of a pharmacopoeia developed within paradigms it critiques. Use it as lens for clinical reasoning, not as validated protocol. The goal is thinking more clearly about what medications do to consciousness, whilst remaining humble about how much we truly understand.
Work in progress—developed in collaboration between clinical experience and field-based consciousness framework.
Further Resources: The Labyrinth
This field-based framework exists within a larger ecosystem of interconnected resources exploring consciousness, psychiatry, and healing:
Accessible Entry Points
These resources provide compassionate, accessible introductions for those new to field-based consciousness frameworks:
- First Light - Poetic introduction to consciousness field theory, bridging lived experience with theoretical understanding[
- A New Way to See Your MindPatient-facing introduction to Spiral State Psychiatry—understanding mental distress as consciousness field disruption rather than broken brain
- Emotional Intensity ToolkitInteractive tool for patients, clinicians, and teams—understanding and working with emotional intensity through G/Γ/Δ² framework, crisis planning, ICD-11 formulation, evidence-based interventions
- Resilience ToolkitPractical exercises for building capacity—window of tolerance, TIPP skills, grounding, urge surfing, thought work
CORE FRAMEWORK
- The Transformation Programme HypothesisThe endogenous transformation programme—why dissolution is not pathology, why meaning determines outcome, and why psychiatry's suppressive approach creates iatrogenic liminality
EPISTEMOLOGICAL FOUNDATION
- Contemporary PsychiatryThe empirical critique—why diagnostic categories fail and what evidence actually shows
BIOLOGICAL SUBSTRATE
- Neuroinflammatory ConsciousnessHow inflammation disrupts consciousness field coherence
COGNITIVE ARCHITECTURE
- Wild-Type Cognition Why certain cognitive architectures are vulnerable to both environmental incoherence and inflammatory disruption
THERAPEUTIC MODALITIES
PSYCHEDELIC PHENOMENOLOGY & PRACTICE
These resources serve as bridges between theoretical understanding and practical application in psychedelic contexts:
- The Muse in the MushroomPsilocybin, creativity, and consciousness—exploring the intersection of neuroscience, mythology, and transformative experience
- Recognition Field Dynamics & Psychedelic Phenomenology - Mapping psychedelic phenomenology onto field dynamics—psi, entity encounters, and consciousness transformation
- Ketamine-Assisted PsychotherapyComprehensive clinical review—consciousness-centered protocols vs medical models, evidence, and implementation
CLINICAL PRACTICE
- Patient Companion App (antidepressant withdrawal)
INTEGRATION TOOLS
These resources form a labyrinth—150+ interconnected sites, each with NotebookLM companions and video overviews, designed for recursive exploration rather than linear consumption.